PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA
· Patent Litigation & Settlement History ↓
Current GenericRadar decision
QUALIFYING_ANCHOR_WITH_LATER_RIGHTS; canonical 2023 DEEP_REVIEW; QUALIFYING_ANCHOR_WITH_LATER_RIGHTS.
Patent estate
| Patent | Effective date | Official listing | TRUE_DS | DS grade | Claim classification / basis | PTE | PED | Family |
|---|---|---|---|---|---|---|---|---|
| No patent facts are recorded for this product. | ||||||||
Regulatory exclusivity
| Code | Start date | End date | Scope | Entire product | All indications | Full coverage date | Combination | Source |
|---|---|---|---|---|---|---|---|---|
| NP | 2016-04-15 | 2019-04-15 | PARTIAL_INDICATION; ODE-116 and ODE-121 jointly cover both current approved diseases. Full union end is the first necessary component end2023-04-15, not2023-07-15. FDA orphan registry confirms each scope independently. These are therapeutic cross-linking uses. | Y | N | — | Source | |
| COMBINATION_ODE116_ODE121 | 2016-07-15 | 2023-04-15 | Full exact-product approved indication and population scope established by the reviewed union of required FDA rights. Meaningful date is the earlier necessary component extended endpoint. Derived review conclusion, not a separate FDA award. ODE-116 and ODE-121 jointly cover both current approved diseases. Full union end is the first necessary component end2023-04-15, not2023-07-15. FDA orphan registry confirms each scope independently. These are therapeutic cross-linking uses. | Y | Y | 2023-04-15 | Source | |
| ODE-116 | 2016-04-15 | 2023-04-15 | COMBINATION_COMPONENT_PARTIAL_INDICATION; ODE-116 and ODE-121 jointly cover both current approved diseases. Full union end is the first necessary component end2023-04-15, not2023-07-15. FDA orphan registry confirms each scope independently. These are therapeutic cross-linking uses. | Y | N | — | Source | |
| ODE-121 | 2016-07-15 | 2023-07-15 | COMBINATION_COMPONENT_PARTIAL_INDICATION; ODE-116 and ODE-121 jointly cover both current approved diseases. Full union end is the first necessary component end2023-04-15, not2023-07-15. FDA orphan registry confirms each scope independently. These are therapeutic cross-linking uses. | Y | N | — | Source |
2026-10-12 · HISTORICAL_RECORDS_RECOVERED · Historical coverage: ANNUALS_2011_2026_REVIEWED
2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE
Generic approval evidence
| Application / product | Event | Final date | Tentative date | Applicant | Authorized generic | Exact mapping | Source |
|---|---|---|---|---|---|---|---|
| No generic approval facts are linked to this product. | |||||||
Market Entry Information
API filings, authorized generics and linked regulatory milestones.
API Master Files & Certifications 0 records
Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.
| API | Holder / manufacturer | Holder country | Filing type | Number | Status | Filed date | Available for reference | Source | Last verified |
|---|---|---|---|---|---|---|---|---|---|
| No master-file or certification records are linked through public manufacturer portfolios. | |||||||||
Authorized Generics 0 records
Authorized generics are shown separately from independent ANDA approvals.
| Application / product | Applicant | Event / status | First marketed | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No authorized-generic records are linked to this product. | ||||||
Tentative ANDA Approvals 0 records
Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.
| Application / product | Applicant | Event / status | Tentative date | Follow-up final approval | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|---|
| No tentative-approval records are linked to this product. | |||||||
Paragraph IV Challenges 0 records
Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.
| Application / product | Applicant | Event / status | Certification event date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No structured Paragraph IV certification events are linked in the available approval evidence. | ||||||
Final ANDA Approvals 0 records
Approval dates do not establish commercial launch. Product mapping is shown for each linked record.
| Application / product | Applicant | Event / status | Final approval date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No final-approval records are linked to this product. | ||||||
Decision evidence (5)
| Type | Date | Role | Basis | Source |
|---|---|---|---|---|
| REGULATORY_EXCLUSIVITY | — | SCOPE_CONTEXT | COMBINATION_COMPONENT_PARTIAL_INDICATION; ODE-116 and ODE-121 jointly cover both current approved diseases. Full union end is the first necessary component end2023-04-15, not2023-07-15. FDA orphan registry confirms each scope independently. These are therapeutic cross-linking uses. | Source |
| REGULATORY_EXCLUSIVITY | — | SCOPE_CONTEXT | PARTIAL_INDICATION; ODE-116 and ODE-121 jointly cover both current approved diseases. Full union end is the first necessary component end2023-04-15, not2023-07-15. FDA orphan registry confirms each scope independently. These are therapeutic cross-linking uses. | Source |
| REGULATORY_EXCLUSIVITY | — | SCOPE_CONTEXT | COMBINATION_COMPONENT_PARTIAL_INDICATION; ODE-116 and ODE-121 jointly cover both current approved diseases. Full union end is the first necessary component end2023-04-15, not2023-07-15. FDA orphan registry confirms each scope independently. These are therapeutic cross-linking uses. | Source |
| REGULATORY_EXCLUSIVITY | 2023-04-15 | CANONICAL_ANCHOR | Full exact-product approved indication and population scope established by the reviewed union of required FDA rights. Meaningful date is the earlier necessary component extended endpoint. Derived review conclusion, not a separate FDA award. ODE-116 and ODE-121 jointly cover both current approved diseases. Full union end is the first necessary component end2023-04-15, not2023-07-15. FDA orphan registry confirms each scope independently. These are therapeutic cross-linking uses. | Source |
| REGULATORY_STATUS | 2023-04-15 | DECISION_BASIS | QUALIFYING_ANCHOR_WITH_LATER_RIGHTS; canonical 2023 DEEP_REVIEW; QUALIFYING_ANCHOR_WITH_LATER_RIGHTS. | Source |
Litigation & Settlement History
Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.
No litigation or settlement record currently linked to this product.